Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies

CONCLUSIONS: We highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel.PMID:38646700 | DOI:10.1080/14737140.2024.2343801

Source: Expert Review of Anticancer Therapy - April 22, 2024 Category: Cancer & Oncology Authors: Olalekan O Oluwole Sattva S Neelapu Markqayne D Ray Eve H Limbrick-Oldfield Sally W Wade Steve Kanters Anik R Patel Frederick L Locke Source Type: research